fda bpc-157 panel backs compounded BPC-157, KPV peptides in win for RFK Jr FDA's own advisory committee voted

FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! FDA Panel Votes to Recommend BPC 157 for Pharmacy Compounding HealingMaps BREAKING: FDA projected to move BPC 157 to Category 1 as panel of advisers weigh looser restrictions on popular peptides. 59% chance.

SKU: 31732730754 · From equiscorp.hu